The objectives of this report are to compare benefits under Canada’s public drug programs in terms of the number of new drugs approved for public insurance, as well as the time that patients must wait for insured access to new medicines, and to compare public drug programs against benchmarks set by private-sector drug insurance in Canada. Read the full report
here.
No comments:
Post a Comment